In the EMPA-REG study, empagliflozin significantly reduced the risk for the composite renal outcome, which included doubling of serum creatinine, progression of macroalbuminuria, initiation of renal replacement therapy, or renal death ( Subsequent studies, such as CREDENCE, DAPA-CKD, and EMPA-KIDNEY, were specifically designed to investigate the renoprotective effects of SGLT-2i
That is my experience
Meanwhile, the ongoing SURMOUNT-MMO trial (clinical trial number NCT05556512
They are developed with Harvard dermatologists and clinically tested on sensitive and melaninrich skin, which sets a high bar for the rest of the products in this list
It remains a research compound, and its effects in humans have not been established through large-scale clinical trials
Keep Out Of Reach Of Children